ProMIS Neurosciences (NASDAQ:PMN) Posts Earnings Results, Beats Expectations By $0.12 EPS

ProMIS Neurosciences (NASDAQ:PMN) posted its quarterly earnings data on Monday. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.12, Zacks reports.

ProMIS Neurosciences Price Performance

NASDAQ PMN traded up $0.04 during mid-day trading on Tuesday, reaching $0.73. 73,038 shares of the stock were exchanged, compared to its average volume of 70,651. The stock has a 50 day simple moving average of $0.82 and a 200-day simple moving average of $0.96. The stock has a market cap of $23.93 million, a P/E ratio of -7.32 and a beta of 0.58. ProMIS Neurosciences has a one year low of $0.62 and a one year high of $2.61.

Analyst Upgrades and Downgrades

Separately, Guggenheim reaffirmed a “buy” rating and set a $6.00 price objective on shares of ProMIS Neurosciences in a research report on Tuesday.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.